

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**LOK SABHA
UNSTARRED QUESTION NO. 3004
TO BE ANSWERED ON THE 06TH AUGUST, 2021**

UTILISATION OF PUBLIC SECTOR VACCINE MANUFACTURING PLANT

3004. DR. KALANIDHI VEERASWAMY:

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) whether the Government is aware that the country is facing shortage of Covid-19 Vaccines, if so, the details thereof and the reasons therefor;
- (b) whether the Government is aware that the Centre's state-of-the-art public sector vaccine manufacturing plant, Integrated Vaccine Complex (IVC), IN Chengalpattu, near Chennai is lying idle for nine years, if so, the details thereof;
- (c) whether the Government is also aware that the IVC has the capacity to produce one billion vaccines annually and it can cater to a large part of the demand of Tamil Nadu as well as the rest of the country, if so, the details thereof; and
- (d) the reasons for non utilization of the IVC for production of Covid-19 Vaccines along with the time by which it will be utilized for production of Covid-19 Vaccines?

ANSWER

**THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY
WELFARE
(DR. BHARATI PRAVIN PAWAR)**

(a) to (d) Government of India has been providing free supply of Covid vaccines in enough quantity to States/UTs for vaccination of prioritized beneficiaries as recommended by National Expert Group on Vaccine Administration for COVID-19 (NEGVAC). Advance visibility of these allocations i.e. the total doses of Covid vaccine that would be available to State/UT, are provided 15 days in advance to all States/UTs so as to enable them to prepare plan for acceleration of Covid vaccination coverage while being cognizant of the availability Covid vaccines.

Government of India has also taken many steps to augment the domestic manufacturing capacity of COVID-19 vaccines. These include support to M/s Bharat Biotech and three Public Sector

Enterprises (PSEs) under ‘Mission COVID Suraksha- the Indian COVID-19 Vaccine Development Mission’, technology transfer of Covaxin production, financial assistance to one of the domestic vaccine manufacturer M/s Biological E for ‘At-risk manufacturing’, advance payment against the supply orders placed with M/s Serum Institute of India and M/s Bharat Biotech, and streamlining of regulatory norms for approval of vaccines.

HLL Biotech Ltd. has established an “Integrated Vaccine Complex” (IVC), at Chengalpattu in Tamil Nadu as a green field project with capacities to “fill and finish” as well as Bulk Production of Vaccines.

HLL has invited expression of interest from vaccine/Pharmaceutical Manufactures for use of HBL's existing facilities at Integrated Vaccine Complex (IVC), Chengalpattu. HLL is also in dialogue with some interested parties for utilizing this IVC facility. Repurposing for production of COVID-19 Vaccine would require certain modifications in the infrastructure like up-gradation of existing biosafety level facilities with certain additional equipments depending upon the technology and vaccine platform taken up for production.
